Medical network - on April 20, according to the 2015 China hypertension guidelines for the rational use of drugs - guidelines, adult patients with high blood pressure at present in China has reached 298 million people. Patients currently witting rate was 46.5%, the treatment was 46.5%, the control of 13.8%. 

 

2017 edition of the national basic medical insurance, inductrial injury insurance and maternity insurance drug catalogue of 21 new cardiovascular drugs, the new 16 hypertension treatment in western medicine, compound preparations 14, accounted for 87.50% of new hypertension treatment. Angiotensin converting enzyme inhibitor compound preparations, the compound preparation of angiotensin Ⅱ antagonists, become the biggest bright spot. 

 

Three pillar 

 

In recent years, with high blood pressure education in our country and the improvement of medication, the majority of the elderly hypertension management improved, objectively promoted the steady growth of hypertension treatment market in our country, but the trend of the development of hypertension younger still make hypertension prevalence rate increased dramatically in our country. 

 

According to the institute of medicine economic south database data, in 2015 China's urban public hospitals, public hospitals at the county level, urban communities, towns and townships, entity pharmacies and store the three terminals 6 big market sales of 38.2 billion yuan, high blood pressure drugs year-on-year growth of 10.72% a year. 

 

 

 

Treatment of hypertension in the market, calcium channel blockers (CCB) and angiotensin receptor blockers (ARB) and compound antihypertension drugs three kinds and has formed the tripartite confrontation. Compound antihypertensive agents is the market growing faster in the category. 

 

Prevention and control of hypertension guidelines emphasize, USES the sequential therapy for hypertension control, combination therapy is based on blood pressure control in drug use. Especially hypertension elderly people for many years, a single drug have been unable to make the blood pressure, choose two or more drugs combination therapy as the preferred solution. Research shows that fixed dose of compound preparations (FDC) hypertension treatment to bring greater benefits, taking compound preparations antihypertensive treatment success rate of fixed dose was obviously higher than that of free combination, can achieve smooth step-down, 24 hours a day has good compliance. 

 

According to 3 quarter data m Intranet HDM system 2016 years ago, the clinical use of antihypertensive compound preparations have fixed 20 drugs, the main varieties of growth. Forecast in 2016 key cities for the domestic public hospital fixed dose of compound antihypertensive drug preparation amount to 843 million yuan, a year-on-year growth of 11.99% a year. Five years the average growth rate of 29.28% in 2011-2016, domestic compound antihypertensive agents market scale has reached 6 billion yuan, predicted in the past two years will exceed ten billion yuan. 

 

 

 

Compound fixed dose antihypertensive medicine perspective 

 

Fixed dose combination ARB class 

 

At present, the clinical use of compound antihypertensive agents, in the first category was seven compound fixed dose of sand class (ARB) preparations, respectively is valsartan amlodipine, hydrochlorothiazide he sand, sand jotham hydrochlorothiazide chloride and valsartan hydrochlorothiazide and telmisartan hydrochlorothiazide, ogilvy sand jotham hydrochlorothiazide and candesartan hydrogen chloride hydrogen thiamethoxam. 

 

Forecast in 2016 key cities for the domestic public hospital fixed dose combination ARB drug preparation amount to 704 million yuan, a year-on-year growth of 10.42% a year. 2011-2016 annual average growth rate of 24.86%, is a compound antihypertensive market leading varieties. 

 

 

 

Compound fixed dose ACEI class 

 

The second category is seven compound fixed dose of captopril (ACEI) drugs, respectively is without perindopril split indapamide and folic acid and hydrochlorothiazide, bei that captopril amlodipine, lisinopril hydrochlorothiazide, bei that captopril hydrochlorothiazide, enalapril hydrochlorothiazide. 

 

In 2016 key cities for the domestic public hospital fixed dose combination of ACEI agents amount is 74.67 million yuan, year-on-year growth of 34.88% a year. 2011-2016 annual average growth rate of 113.49%. Sum of growth faster drug is servier (tianjin) pharmaceutical without the split indapamide (zyprexa), shenzhen osama pharmaceutical enalaprilat folic acid (in accordance with the leaf), thus promote the rapid growth of this kind of drugs. 

 

 

 

Other types of compound antihypertensive agents 

 

The third kind is the other kind of compound antihypertensive agents, mainly amlodipine atonrastatin statin calcium, reserpine ammonia benzene pteridine, amiloride hydrochlorothiazide, blood group of bisoprolol and compound peace compound double hydrazine flexor oxazine etc. 6 drugs. 

 

Public hospital other classes of the key cities for the 2016 domestic compound antihypertensive drug preparation amount to 64.54 million yuan, year-on-year growth of 8.84% a year. Pfizer amlodipine atonrastatin statin calcium (commodity called up to 1) as the leading varieties, two other faster-growing is confirmed potassium diuresis antihypertensives amiloride hydrochlorothiazide tablet and jiangsu pharmaceutical co., group horizon and atenolol compound preparations, bisoprolol group. 

 

Detail of TOP 10 compound antihypertensive agents 

 

The mechanism of high blood pressure are still not fully understand, need a variety of methods to prevent high blood pressure, reduce heart load and the influence on coronary artery, which is the basis of the combination. Internationally, fixed dose formula for its small small dosage, high curative effect, side effects and has played a good benefit. 

 

On the market in China, the TOP 10 varieties compound antihypertensive drugs before five drugs are valsartan amlodipine piece, he sha Tanzania hydrochlorothiazide tablet and capsule hydrochlorothiazide tablets, chlorine, valsartan and hydrochlorothiazide tablets capsule and amlodipine atorvastatin piece, the five varieties market share occupied 88% of the total amount of compound antihypertensive agents. 

 

Compound antihypertensive drugs after the TOP 10 varieties of five drugs without perindopril split indapamide and folic acid pills, telmisartan and hydrochlorothiazide tablets capsule and amlodipine bei that captopril tablet, ogilvy sand hydrochlorothiazide tablets. This a few varieties of drugs is nearly two years of high growth, in 2016 year-on-year growth rate of more than 30% in the previous year. 

 

Valsartan amlodipine 

 

Valsartan amlodipine is compound antihypertensive drugs market ranks first. The drug developed by novartis, Switzerland, angiotensin receptor blockers (arbs) are valsartan (Diovan) and calcium channel blockers (CCB) amlodipine (Norvasc) fixed formula. On June 20, 2007 for FDA approal, commodity name Exforge, thus promote the valsartan series of drug market. 2016 series of valsartan novartis drug market scale has reached $4.168 billion, the Chinese valsartan series of drug market size of more than 3 billion yuan. 

 

2009 valsartan amlodipine piece into the domestic market, public hospital commodity called times talbot, is the domestic exclusive varieties. In 2016 key cities for the domestic public hospital times bothe drug amount is 280 million yuan, a year-on-year growth of 16.74% a year. 

 

 

 

He sand hydrochlorothiazide 

 

He sand jotham hydrochlorothiazide developed by sanofi company, called Coaprovel goods. Is now on the market in China, commodity called ember, ember in 2015 at the domestic occupies 3.83% share of the cardiovascular system medicine field. 

 

In 2016 key cities for the domestic public hospital er bei sha Tanzania hydrochlorothiazide use amount is 170 million yuan, a year-on-year growth of 6.01% a year. 8 CFDA has approved domestic listed companies' products, the original drugs on the market in a public hospital ember occupy 61.92%, zhengda accounted for 21.76%, the weather is fine in Inner Mongolia yuanhe accounted for 9.14%, huahai pharmaceutical industry accounts for 3.54, high pharmaceutical is occupied 3.13%, other 0.51%. 

 

Chlorine sand hydrochlorothiazide 

 

2016 key cities for the domestic public hospital chlorine sand jotham hydrochlorothiazide use amount is 140 million yuan, a year-on-year growth of 7.38% a year. The original medicine is the sea express of MSD, the CFDA has approved domestic listed six varieties of the production of enterprises, respectively is Wan Sheng pharmaceutical, suzhou east Beijing rui double auspicious pharmaceutical pharmaceutical, Beijing, shandong sym pharmaceutical, tianjin new pharmaceutical development of new pharmaceutical and henan meihua pharmaceutical, including the original medicine sea and occupied more than 70% of the share. 

 

Chlorine sand jotham hydrochlorothiazide is FDA approved indications for the treatment of left ventricular hypertrophy of new drugs, used in patients with high blood pressure. Chlorine sand jotham 50 mg + 12.5 mg hydrochlorothiazide clinical application widely in our country, chlorine sand temple 100 mg + 12.5 mg hydrochlorothiazide product launches, added new options to the poor conductivity administration. 

 

Valsartan hydrochlorothiazide 

 

Valsartan hydrochlorothiazide original drugs are Swiss novartis's generation. The CFDA has approved nine domestic enterprises listed products production. In 2016 key cities for the domestic public hospital valsartan hydrochlorothiazide use amount is 86.5 million yuan, a year-on-year growth of 3.12% a year. From the point of market competition, after generation accounted for 84.16%; Chinese medicine in jiangsu province high company occupy 11.48%, China resources secco occupy 2.79%, other 1.57%. 

 

Amlodipine atorvastatin 

 

Amlodipine atorvastatin calcium tablet is Pfizer sole products in China's listed in the United States, called up to the goods. In 2016 key cities for the domestic public hospitals as much as a medicine for more than 6000 ten thousand yuan, year-on-year growth of 18.95% last year, is only breed in the compound antihypertension cholesterol-lowering drugs. 

 

 

 

Atorvastatin on lipid market leader for many years, in 2015, Pfizer China atorvastatin calcium tablet sales of 7.782 billion yuan, amlodipine piece is 4.371 billion yuan. The data shows that this is a great market potential. 

 

Up to a domestic numerous imitators, headed by Beijing jia Lin pharmaceutical co., a total of 25 companies sought. With amlodipine of atorvastatin continuously improve production technology, part of the declaration drug manufacturer has reached delivery system consistent with the original structure of drugs, consistent, bioavailability, dissolution and the original medicine no difference. Domestic drug post-marketing will break the original medicine pattern of unify the whole country, and also benefit patients with hypertension and hyperlipidemia. 

 

Enalaprilat folic acid 

 

Enalaprilat folic acid in compound antihypertensive drugs ranked eighth in the top 10, maintained high growth rates for its unique mechanism of action. Enalaprilat folic acid is shenzhen osama pharmaceutical research and development of new varieties, used to treat associated with elevated plasma homocysteine levels of primary hypertension. 

 

2010 CFDA approval shenzhen osama enalaprilat folic acid tablets on the market goods, in accordance with the leaves. Folic acid maleic acid enalaprilat lower hypertension patient's blood pressure, plasma homocysteine levels can be reduced. In 2016 key cities for the domestic public hospital enalaprilat folic acid tablets drug amount is 25.3 million yuan, year-on-year growth of 35.76% last year, is expected in the next few years has been a steady rise in sales.